Growth Metrics

Gilead Sciences (GILD) Revenue (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -12.18%
Dec 31, 2025 2.01%
Sep 30, 2025 9.70%
Jun 30, 2025 6.22%
Mar 31, 2025 -11.92%
Dec 31, 2024 0.32%
Sep 30, 2024 8.50%
Jun 30, 2024 4.01%
Mar 31, 2024 -6.02%
Dec 31, 2023 0.89%
Sep 30, 2023 6.85%
Jun 30, 2023 3.89%
Mar 31, 2023 -14.03%
Dec 31, 2022 4.93%
Sep 30, 2022 12.49%
Jun 30, 2022 -5.01%
Mar 31, 2022 -9.03%
Dec 31, 2021 -2.39%
Sep 30, 2021 19.37%
Jun 30, 2021 -3.21%
Mar 31, 2021 -13.45%
Dec 31, 2020 12.83%
Sep 30, 2020 27.88%
Jun 30, 2020 -7.30%
Mar 31, 2020 -5.63%
Dec 31, 2019 4.91%
Sep 30, 2019 -1.42%
Jun 30, 2019 7.65%
Mar 31, 2019 -8.87%
Dec 31, 2018 3.56%
Sep 30, 2018 -0.92%
Jun 30, 2018 11.01%
Mar 31, 2018 -14.47%
Dec 31, 2017 -8.65%
Sep 30, 2017 -8.81%
Jun 30, 2017 9.78%
Mar 31, 2017 -11.13%
Dec 31, 2016 -2.40%
Sep 30, 2016 -3.55%
Jun 30, 2016 -0.23%
Mar 31, 2016 -8.37%
Dec 31, 2015 2.54%
Sep 30, 2015 0.62%
Jun 30, 2015 8.56%
Mar 31, 2015 3.83%
Dec 31, 2014 21.05%
Sep 30, 2014 -7.54%
Jun 30, 2014 30.73%
Mar 31, 2014 60.22%
Dec 31, 2013 12.11%
Sep 30, 2013 0.58%
Jun 30, 2013 9.28%
Mar 31, 2013 -2.17%
Dec 31, 2012 6.66%
Sep 30, 2012 0.89%
Jun 30, 2012 5.38%
Mar 31, 2012 3.73%
Dec 31, 2011 3.71%
Sep 30, 2011 -0.73%
Jun 30, 2011 10.96%
Mar 31, 2011 -3.63%
Dec 31, 2010 3.15%
Sep 30, 2010 0.54%
Jun 30, 2010 -7.60%
Mar 31, 2010 2.63%
Dec 31, 2009 12.82%
Sep 30, 2009 9.36%
Jun 30, 2009 7.62%